Please provide your email address to receive an email when new articles are posted on . Use of a single inhaler with albuterol and corticosteroids as needed reduced exacerbations by 26%. As-needed ...

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...

BOSTON -- Inhaled corticosteroids (ICS) combined either with formoterol (Foradil) or short-acting beta-agonists (SABA) for asthma treatment were associated with reduced risks of severe exacerbations ...

Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler ...

It also looks at whether increasing ICS to high doses is an alternative to OCS, as well as the effects of increasing the dose of combination therapy during exacerbations. Use of inhaled ICS/LABA for ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide ...

AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...

Efficacy trials suggest that extra-fine particle beclometasone dipropionate-formoterol (efBDP-FOR) is comparable to fluticasone propionate-salmeterol (FP-SAL) in preventing asthma exacerbations at a ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily ...

What to do when a patient’s asthma control deteriorates after switching to a more environmentally friendly, or ‘greener’, ...